RX Review: Updates in Pediatric Food Allergy and Anaphylaxis for 2025 - Episode 2
In this video, part 2 of a 5-part series, panelists discuss unmet needs in pediatric food allergy research and clinical care.
In this HCPLive and Contemporary Pediatrics RX Review special report, Brian Schroer, MD leads a discussion with Colleen Kraft, MD, and Russell Traister, MD, on unmet needs in pediatric food allergy research and clinical care.
Kraft emphasizes the ongoing confusion in primary care about distinguishing food allergies from intolerances, particularly IgE-mediated allergies, like peanut allergy, versus non-IgE conditions, such as food protein-induced enterocolitis syndrome (FPIES). She highlights the need for clearer education on individualized management plans and emergency preparedness.
Traister points to similar challenges in adult care, where food intolerance is often mistaken for allergy, complicating diagnosis and treatment. Both experts stress the importance of cross-specialty collaboration—such as with gastroenterologists—and better allergy education for residents and medical students, many of whom receive limited formal training in allergy and immunology.
Schreor underscores the need to update allergists and primary care providers alike on evolving food allergy management strategies, from early allergen introduction to biologics like omalizumab (Xolair) and epinephrine nasal spray. He also highlights the updated 2023 anaphylaxis management guidelines, which now advise that patients who respond to self-administered epinephrine may not always require an ER visit—an important shift for schools, daycares, and families.
Part 1: RX Review: Advances in Pediatric Food Allergy and Anaphylaxis Management
Part 3: RX Review: Needle-Free Epinephrine and Emerging Food Allergy Treatments
Part 4: RX Review: Closing Gaps in Clinician Education on Food Allergies
Part 5: RX Review: Innovations in Food Allergy and Anaphylaxis Research
Our Panelists:
Brian Schroer, MD, is an allergist immunologist at the Cleveland Clinic Children's Hospital. Board-certified in internal medicine, pediatrics, and allergy and immunology, Schroer serves as the moderator for this panel discussion.
Colleen Kraft, MD, is a clinical professor of Pediatrics at the Keck School of Medicine of USC and an attending physician at the Children’s Hospital Los Angeles. In addition to these roles, Kraft is also the former president of the American Academy of Pediatrics.
Russell Traister, MD, is a pediatric allergy and immunology specialist at Allegheny Health Network’s Pediatric Institute. Board-certified in allergy, immunology, and internal medicine, Traister serves as the third panelist for our discussion.
Relevant disclosures for Schroer include Genzyme, AstraZeneca, Amgen, GSK, and Sobi. Relevant disclosures for Kraft include Sanofi and Sobi. Relevant disclosures for Traister include Abbvie.
